cyc 202 has been researched along with evodiamine in 1 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (evodiamine) | Trials (evodiamine) | Recent Studies (post-2010) (evodiamine) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 336 | 1 | 240 |
| Protein | Taxonomy | cyc 202 (IC50) | evodiamine (IC50) |
|---|---|---|---|
| Transient receptor potential cation channel subfamily V member 1 | Rattus norvegicus (Norway rat) | 0.44 | |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 2.1 | |
| Cholinesterase | Equus caballus (horse) | 4.62 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, MJ; Hsu, JM; Kan, SF; Pu, HF; Wang, PS; Yu, CH | 1 |
1 other study(ies) available for cyc 202 and evodiamine
| Article | Year |
|---|---|
Anti-proliferative effects of evodiamine on human prostate cancer cell lines DU145 and PC3.
Topics: Androgens; Apoptosis; Carcinoma; Caspase 3; Caspase 8; Caspase 9; CDC2 Protein Kinase; Cell Division; Cell Line, Tumor; Culture Media; Cyclin B; Cyclin B1; DNA Fragmentation; DNA, Neoplasm; Dose-Response Relationship, Drug; Flow Cytometry; G2 Phase; Humans; L-Lactate Dehydrogenase; Male; Plant Extracts; Prostatic Neoplasms; Purines; Quinazolines; Roscovitine | 2007 |